The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. (July 2017)

• Record Type: Journal Article
• Authors: Goebell, Peter J; Doehn, Christian; Grüllich, Carsten; Grünwald, Viktor; Steiner, Thomas; Ehneß, Rainer; Welslau, Manfred
• Is Part Of: Future oncology. Volume 13:Number 17(2017)
• Page Start: 1463
• Page End: 1471
• Publication Date: 2017-07
• Subjects: Afinitor -- everolimus -- metastatic renal cell carcinoma -- mRCC -- nivolumab -- noninterventional -- Opdivo -- pazopanib -- PAZOREAL -- Votrient; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0083
• Languages: English
• ISSNs: 1479-6694

Abstract

VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Europe for use in mRCC after previous therapy. Prospective routine data on sequential therapy including nivolumab and/or lenvatinib are missing. This is a prospective, noninterventional study, which evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab. Adults with histologically confirmed mRCC of any subtype, who have a life expectancy of at least 6 months, are eligible.